eligibility_summary
Eligible: Adults (≥18) with B‑cell non‑Hodgkin lymphoma scheduled for CAR‑T per AIFA indications, with pre‑treatment 18F‑FDG PET/CT or full‑dose non‑contrast CT available, and who provide written informed consent. Excludes anyone not meeting these criteria.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: Chimeric Antigen Receptor T-cell (CAR-T) therapy—an adoptive cellular immunotherapy using autologous, gene-modified T cells. Mechanism: patient T cells are engineered to express CARs that bind surface antigens on B-cell lymphoma cells, leading to HLA-independent T-cell activation, cytokine release, and cytotoxic tumor cell killing. Targets: malignant B cells in B-cell non-Hodgkin lymphoma, key pathways include T-cell activation/cytotoxicity and immune effector signaling. Note: observational study, CAR-T is given per routine care.